Abstract Details

Title Long-Term Impact of Fremanezumab on Headache-Related Disability, Quality of Life, and Patient Satisfaction in Episodic Migraine and Chronic Migraine

Topic Headache

Presentation(s) P2 - Poster Session 2 (5:30 PM-6:30 PM)

Poster/Presentation
Number 13-023

Objective To evaluate the long-term impact of fremanezumab on disability, quality of life (QoL), and satisfaction in adults with chronic migraine (CM) or episodic migraine (EM).

Background

Migraine is a leading cause for years lived with disability worldwide. Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), is approved in the US for the preventive treatment of migraine.

Design/Methods In this 52-week, multicenter, randomized, double-blind, parallel-group study, patients with CM or EM received either subcutaneous fremanezumab monthly (225 mg every month; starting dose of 675 mg) or quarterly (675 mg every 3 months). The effect of fremanezumab on headache-related disability was assessed in CM patients (Migraine Disability Assessment [MIDAS] questionnaire) and in EM patients (six-item Headache Impact Test [HIT-6]). QoL and patient satisfaction were assessed using the Migraine-Specific Quality of Life (MSQoL) questionnaire and the Patient Global Impression of Change (PGIC) scale, respectively.

Results In CM patients, the mean change in HIT-6 scores from baseline to Month 12 was –7.7 with quarterly dosing and –8.4 with monthly dosing. In EM patients, the mean change in MIDAS scores from baseline to Month 12 was –26.0 with quarterly dosing and –27.4 with monthly dosing. Increases from baseline to Month 12 in MSQoL Role Function-Restrictive (CM quarterly: 24.3; CM monthly: 25.8; EM quarterly: 24.6: EM monthly: 26.0), Role Function-Preventive (CM quarterly: 17.2; CM monthly: 18.2; EM quarterly: 18.7; EM monthly: 19.0), and Emotional State (CM quarterly: 23.9; CM monthly: 25.3; EM quarterly: 24.3; EM monthly: 25.4) score subdomains were observed. The majority of patients rated their symptoms as “better” or “a great deal better” when assessed with the PGIC scale at the end of treatment.

Conclusions Long-term treatment with fremanezumab resulted in progressive improvements in disability and QoL in patients with EM and CM.

Authors/Disclosures
PRESENTER	No disclosure on file
Nicolas Saikali, MD	Dr. Saikali has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for AbbVie. Dr. Saikali has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Lilly. Dr. Saikali has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Teva. Dr. Saikali has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Upsher-Smith. Dr. Saikali has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Axsome. The institution of Dr. Saikali has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Lundbeck.
Paul P. Yeung, MD, PhD	No disclosure on file
	No disclosure on file
Xiaoping Ning (Teva pharmaceuticals)	Ms. Ning has received personal compensation for serving as an employee of Teva Pharmaceutical . Ms. Ning has received personal compensation for serving as an employee of Teva Pharmaceutical.

��ɫ��

��ɫ��